Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Gossamer Bio Inc (GOSS)  
$1.17 0.06 (4.88%) as of 4:30 Wed 3/27


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 225,410,000
Market Cap: 263.73(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.4783 - $1.82
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    : 8
Insider 3/6 Months : 8.6
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Co.'s clinical-stage product candidates include: Seralutinib, also known as GB002, which is an inhaled small molecule, platelet-derived growth factor receptor colony-stimulating factor 1 receptor and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, which is an oral small molecule for the treatment of inflammatory bowel disease; and GB5121, which an oral small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 232,000 287,000 1,400,505
Total Buy Value $0 $138,093 $194,188 $2,465,139
Total People Bought 0 2 2 5
Total Buy Transactions 0 2 3 12
Total Shares Sold 8,036 8,036 9,850 57,244
Total Sell Value $10,685 $10,685 $13,025 $303,951
Total People Sold 2 2 2 3
Total Sell Transactions 2 2 3 12
End Date 2023-12-28 2023-09-26 2023-03-28 2022-03-28

   
Records found: 27
  Page 1 of 2  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Carter Laura Chief Scientific Officer   •       –      –    2022-07-01 4 S $8.25 $72,648 D/D (8,808) 80,234 -24%     
   Aranda Richard Chief Medical Officer   •       –      –    2022-06-22 4 S $6.88 $12,233 D/D (1,778) 209,897 -49%     
   Carter Laura Chief Scientific Officer   •       –      –    2022-05-04 4 S $7.20 $9,086 D/D (1,262) 89,042 -93%     
   Giraudo Bryan COO/CFO   •       –      –    2022-03-23 4 S $8.92 $95,587 D/D (10,722) 99,167 -34%     
   Hasnain Faheem President & CEO   •       •      –    2022-03-23 4 S $8.92 $169,697 D/D (19,035) 143,465 -34%     
   Christian Waage EVP, Tech Ops and Admin   •       –      –    2022-03-23 4 S $8.92 $95,587 D/D (10,722) 579,008 -34%     
   Aranda Richard Chief Medical Officer   •       –      –    2022-03-16 4 S $8.28 $51,976 D/D (6,278) 211,675 -35%     
   Peterson Caryn EVP, Regulatory Affairs   •       –      –    2022-03-16 4 S $8.28 $51,978 D/D (6,279) 66,172 -35%     
   Carter Laura Chief Scientific Officer   •       –      –    2022-03-16 4 S $8.28 $41,407 D/D (5,002) 90,304 -35%     
   Carter Laura Chief Scientific Officer   •       –      –    2021-10-25 4 S $12.25 $29,118 D/D (2,377) 95,306 27%     
   Peterson Caryn EVP, Regulatory Affairs   •       –      –    2021-10-25 4 S $12.25 $29,118 D/D (2,377) 72,451 27%     
   Aranda Richard Chief Medical Officer   •       –      –    2021-10-25 4 S $12.25 $29,118 D/D (2,377) 217,432 27%     
   Carter Laura Chief Scientific Officer   •       –      –    2021-06-30 4 A $0.00 $0 D/D 25,000 97,683     -
   Aranda Richard Chief Medical Officer   •       –      –    2021-06-21 4 A $0.00 $0 D/D 15,000 219,809     -
   Carter Laura Chief Scientific Officer   •       –      –    2021-05-03 4 A $0.00 $0 D/D 10,820 72,683     -
   Peterson Caryn EVP, Regulatory AffairsOfficer   •       –      –    2021-04-16 3 IO $0.00 $0 D/D 0 64,008 13%     
   Peterson Caryn EVP, Regulatory Affairs   •       –      –    2021-04-16 4 A $0.00 $0 D/D 10,820 74,828     -
   Salter-Cid Luisa Chief Scientific Officer   •       –      –    2021-03-23 4 S $9.48 $52,052 D/D (5,491) 206,065 16%     
   Christian Waage EVP & General Counsel   •       –      –    2021-03-23 4 S $9.48 $52,051 D/D (5,490) 588,199 16%     
   Giraudo Bryan Chief Financial Officer   •       –      –    2021-03-23 4 S $9.48 $52,046 D/D (5,490) 109,889 16%     
   Christian Waage EVP & General Counsel   •       –      –    2021-02-25 4 A $0.00 $0 D/D 45,000 593,689     -
   Giraudo Bryan Chief Financial Officer   •       –      –    2021-02-25 4 A $0.00 $0 D/D 45,000 115,379     -
   Salter-Cid Luisa Chief Scientific Officer   •       –      –    2021-02-25 4 A $0.00 $0 D/D 45,000 211,556     -
   Hasnain Faheem President & CEO   •       •      –    2021-02-25 4 A $0.00 $0 D/D 162,500 162,500     -
   Christian Waage EVP & General Counsel   •       –      –    2020-10-14 4 B $9.53 $23,818 I/I 2,500 6,954 1.99 11%     

  27 Records found
  1  2   
  Page 1 of 2
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed